Rilonacept
IL-1 decoy receptor (IL-1 Trap)
- Response rate
- Limited data
- Onset
- Weeks
- Route
- SC 160mg load, then 80mg weekly
- Line
- Alternative
- IgM effect
- No effect
Evidence summary
Dimeric fusion protein acting as IL-1 'trap', neutralising both IL-1α and IL-1β. Krause et al. 2012 demonstrated efficacy and safety in an open-label study in Schnitzler syndrome. Less widely used than anakinra/canakinumab.